Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CPRX

Catalyst Pharmaceuticals Inc

Sep 15 • 04:00PM ET

19.76

-0.21 -1.05 %

Healthcare • Biotechnology • USA • NASD

Peers: AXSM AMLX SUPN ENTA ITCI PRTA RDUS XENE ALKS

| Held by: IJR VTI IWM AVUV VXF XBI IWO SPSM IJT VTWO

Scroll to Statements

Index	RUT	P/E	11.99	EPS (ttm)	1.65	Insider Own	8.89%	Shs Outstand	122.39M	Perf Week	-1.59%
Market Cap	2.42B	Forward P/E	11.52	EPS next Y	1.72	Insider Trans	-5.98%	Shs Float	111.42M	Perf Month	-1.54%
Enterprise Value	1.77B	PEG	1.06	EPS next Q	0.33	Inst Own	81.86%	Short Float	7.12%	Perf Quarter	-16.02%
Income	208.66M	P/S	4.33	EPS this Y	11.15%	Inst Trans	3.10%	Short Ratio	5.44	Perf Half Y	-5.99%
Sales	558.50M	P/B	2.83	EPS next Y	17.86%	ROA	24.87%	Short Interest	7.93M	Perf YTD	-5.32%
Book/sh	6.99	P/C	3.70	EPS next 5Y	11.31%	ROE	28.49%	52W High	26.58 -25.66%	Perf Year	1.54%
Cash/sh	5.33	P/FCF	8.80	EPS past 3/5Y	52.99% 34.27%	ROIC	24.30%	52W Low	19.15 3.19%	Perf 3Y	29.57%
Dividend Est.	-	EV/EBITDA	6.29	Sales past 3/5Y	51.71% 36.89%	Gross Margin	79.08%	Volatility	2.90% 3.39%	Perf 5Y	539.48%
Dividend TTM	-	EV/Sales	3.17	EPS Y/Y TTM	196.96%	Oper. Margin	43.58%	ATR (14)	0.69	Perf 10Y	434.05%
Dividend Ex-Date	-	Quick Ratio	6.55	Sales Y/Y TTM	28.55%	Profit Margin	37.36%	RSI (14)	42.79	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	6.71	EPS Q/Q	24.88%	SMA20	-2.27%	Beta	0.80	Target Price	34.29
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	19.44%	SMA50	-4.48%	Rel Volume	1.14	Prev Close	19.97
Employees	181	LT Debt/Eq	0.00	Earnings	Aug 06 AMC	SMA200	-11.30%	Avg Volume	1.46M	Price	19.76
IPO	Nov 08, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.59% 4.35%	Trades		Volume	1,669,272	Change	-1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-25	Initiated	Robert W. Baird	Outperform	$28
Nov-18-24	Initiated	Stephens	Overweight	$35
Mar-14-24	Initiated	Citigroup	Buy	$27
Mar-07-24	Initiated	BofA Securities	Buy	$23
Dec-21-23	Initiated	Oppenheimer	Outperform	$30
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral	$10 → $15.50
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral	$6 → $1
Sep-30-14	Reiterated	ROTH Capital	Buy	$5 → $6
Sep-16-14	Reiterated	ROTH Capital	Buy	$3.50 → $5
Sep-15-14	Reiterated	H.C. Wainwright	Buy	$5 → $13
Oct-21-13	Reiterated	Aegis Capital	Buy	$4 → $5.50
Sep-24-13	Initiated	Maxim Group	Buy	$4
Sep-06-13	Reiterated	Aegis Capital	Buy	$3.50 → $4
Apr-18-13	Initiated	Aegis Capital	Buy	$2.50
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform	$3.70
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell

Show Previous Ratings

Today 09:40AM	Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Sep-02-25 04:26PM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-29-25 09:40AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
04:54AM	Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035 (Insider Monkey)
Aug-28-25 08:03AM	Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:12PM	Loading…
Aug-26-25 07:12PM	UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals (GlobeNewswire)
11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks)
Aug-25-25 08:03AM	Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals (GlobeNewswire)
Aug-15-25 09:45AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock (Zacks)
Aug-13-25 09:40AM	Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term (Zacks)
Aug-07-25 10:08AM	Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks) -9.89%
09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-06-25 07:00PM	Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:40PM	Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates (Zacks)
05:37PM	Catalyst: Q2 Earnings Snapshot (Associated Press Finance)
04:13PM	Loading…
04:13PM	Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update (GlobeNewswire)
08:03AM	Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) (GlobeNewswire)
Aug-05-25 09:40AM	Catalyst Pharmaceuticals Inc (CPRX) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Aug-04-25 08:03AM	Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors (GlobeNewswire)
Aug-01-25 09:40AM	Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-24-25 09:45AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock (Zacks)
04:04AM	Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group (Zacks)
Jul-23-25 10:35AM	Rising Cash Flows Make These 4 Stocks Worth Choosing Now (Zacks)
Jul-22-25 08:07AM	Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns (Zacks)
08:03AM	Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-21-25 09:40AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
09:40AM	Loading…
Jul-16-25 09:40AM	Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? (Zacks)
09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-09-25 11:40AM	CPRX or STVN: Which Is the Better Value Stock Right Now? (Zacks)
Jul-07-25 09:45AM	Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term (Zacks)
Jul-04-25 09:40AM	Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term (Zacks)
Jun-30-25 09:40AM	Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? (Zacks)
Jun-26-25 09:35AM	Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jun-23-25 11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-19-25 09:45AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock (Zacks)
Jun-18-25 09:40AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
Jun-17-25 08:23AM	4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns (Zacks)
Jun-10-25 09:15AM	Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jun-06-25 03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
11:31AM	Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue? (Zacks)
09:50AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
Jun-04-25 12:00PM	What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now? (Zacks)
08:30AM	If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
09:45AM	Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term (Zacks)
Jun-02-25 09:55AM	Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect? (Zacks)
09:40AM	Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term (Zacks)
09:40AM	Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:50AM	Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
08:03AM	Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer (GlobeNewswire)
May-09-25 03:18AM	Catalyst Pharmaceuticals Inc (CPRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-08-25 10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
May-07-25 07:00PM	Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics (Zacks)
06:25PM	Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates (Zacks)
05:27PM	Catalyst: Q1 Earnings Snapshot (Associated Press Finance)
04:14PM	Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:58AM	Catalyst Pharmaceuticals Inc (CPRX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-01-25 10:01AM	Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 10:01AM	Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:03AM	Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 (GlobeNewswire)
Apr-27-25 03:16PM	Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now (Insider Monkey)
Apr-22-25 08:03AM	Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-11-25 12:59PM	Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? (Insider Monkey)
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Apr-08-25 03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:06AM	Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals (GlobeNewswire)
08:00AM	New Drug Submission for AGAMREE (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy (PR Newswire)
Apr-03-25 04:50PM	Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday (Motley Fool)
Apr-02-25 08:19AM	What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? (Insider Monkey)
Mar-30-25 06:50AM	abrdn U.S. Small Cap Equity Fund Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 11:30AM	Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-27-25 12:21PM	Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win (Investor's Business Daily)
10:45AM	Jim Cramer on Catalyst Pharmaceuticals (CPRX): 'That's My Kind of Stock!' (InsiderMonkey)
09:32AM	Wright: Tariffs could negatively impact the automobile consumer discretionary sector. (CNBC TV)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-14-25 10:54AM	Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-04-25 08:03AM	Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference (GlobeNewswire)
Feb-28-25 02:14AM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +5.68%
Feb-27-25 02:35PM	Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today (Motley Fool) +5.25%
Feb-26-25 08:30PM	Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates (Zacks)
05:53PM	Catalyst: Q4 Earnings Snapshot (Associated Press Finance)
04:13PM	Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:31AM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-25 10:23AM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-18-25 04:25PM	Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 (Investor's Business Daily)
04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
Feb-12-25 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 (GlobeNewswire)
Jan-31-25 08:00AM	This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry (Investor's Business Daily)
Jan-30-25 03:32PM	Harmony Biosciences Stock Scores 80-Plus RS Rating (Investor's Business Daily)
Jan-24-25 09:50AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
Jan-23-25 08:03AM	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies (GlobeNewswire)
Jan-21-25 08:19AM	Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan (GlobeNewswire)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)
Jan-09-25 08:17AM	Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? (Zacks)

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 08 '25	Option Exercise	2.24	112,475	251,944	301,039	Sep 10 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 08 '25	Sale	20.30	30,000	609,000	271,039	Sep 10 05:00 PM
Elsbernd Brian	Officer	Sep 08 '25	Proposed Sale	20.30	30,000	609,035		Sep 08 02:52 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 04 '25	Option Exercise	2.24	30,000	67,200	218,564	Sep 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 03 '25	Option Exercise	2.24	20,000	44,800	208,564	Sep 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 04 '25	Sale	19.52	30,000	585,600	188,564	Sep 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 03 '25	Sale	20.08	20,000	401,600	188,564	Sep 05 05:00 PM
Elsbernd Brian	Officer	Sep 04 '25	Proposed Sale	19.52	30,000	585,641		Sep 04 11:28 AM
Elsbernd Brian	Officer	Sep 03 '25	Proposed Sale	20.08	20,000	401,514		Sep 03 12:19 PM
Tierney David S	Director	Aug 27 '25	Option Exercise	2.24	50,000	112,000	405,620	Aug 28 05:00 PM
Tierney David S	Director	Aug 27 '25	Sale	20.20	26,000	525,200	379,620	Aug 28 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 26 '25	Option Exercise	2.24	115,000	257,600	1,064,663	Aug 28 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 27 '25	Option Exercise	2.24	110,000	246,400	1,059,663	Aug 28 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 26 '25	Sale	20.28	115,000	2,332,200	949,663	Aug 28 05:00 PM
Daly Richard J	President and CEO	Aug 26 '25	Option Exercise	2.24	50,000	112,000	249,764	Aug 28 05:00 PM
Daly Richard J	President and CEO	Aug 26 '25	Sale	20.62	22,970	473,641	226,794	Aug 28 05:00 PM
Tierney David S	Director	Aug 27 '25	Proposed Sale	20.20	26,000	525,088		Aug 27 04:14 PM
Miller Steve	Officer	Aug 26 '25	Proposed Sale	20.28	115,000	2,332,370		Aug 26 01:07 PM
Daly Richard J	Officer	Aug 26 '25	Proposed Sale	20.62	22,970	473,641		Aug 26 10:46 AM
Sundaram Preethi	Chief Strategy Officer	Jun 10 '25	Sale	26.41	2,324	61,377	42,681	Jun 12 05:00 PM
Sundaram Preethi	Chief Strategy Officer	Jun 11 '25	Sale	26.42	1,600	42,272	41,081	Jun 12 05:00 PM
Sundaram Preethi	Officer	Jun 11 '25	Proposed Sale	26.42	1,600	42,268		Jun 11 04:21 PM
MCENANY PATRICK J	Chairman of Board of Directors	Jun 09 '25	Sale	26.11	171,748	4,484,340	4,281,702	Jun 10 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Jun 06 '25	Sale	25.95	28,252	732,998	4,453,450	Jun 10 05:00 PM
Sundaram Preethi	Officer	Jun 10 '25	Proposed Sale	26.41	2,324	61,383		Jun 10 04:13 PM
MCENANY PATRICK J	Director	Jun 06 '25	Proposed Sale	25.88	200,000	5,176,000		Jun 06 03:42 PM
O'Keeffe Charles B	Former Director	Jun 02 '25	Proposed Sale	25.00	8,222	205,550		Jun 02 02:44 PM
O'Keeffe Charles B	Former Director	May 30 '25	Proposed Sale	25.01	41,778	1,044,973		May 30 04:32 PM
Daly Richard J	Officer	May 30 '25	Proposed Sale	24.86	70,000	1,740,172		May 30 04:04 PM
INGENITO GARY	Chief Med. & Reg. Officer	May 13 '25	Option Exercise	3.42	200,000	684,000	268,873	May 15 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	May 14 '25	Option Exercise	4.64	44,000	204,160	112,873	May 15 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	May 13 '25	Sale	23.68	200,000	4,736,000	68,873	May 15 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	May 14 '25	Sale	23.63	44,000	1,039,720	68,873	May 15 05:00 PM
INGENITO GARY	Officer	May 14 '25	Proposed Sale	23.63	44,000	1,039,720		May 14 10:45 AM
INGENITO GARY	Officer	May 13 '25	Proposed Sale	23.98	200,000	4,796,000		May 13 11:14 AM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 06 '25	Option Exercise	2.24	180,096	403,415	248,969	Mar 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 05 '25	Option Exercise	2.24	44,904	100,585	113,777	Mar 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 06 '25	Sale	21.67	180,096	3,902,680	68,873	Mar 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 05 '25	Sale	22.09	44,904	991,929	68,873	Mar 07 05:00 PM
INGENITO GARY	Officer	Mar 06 '25	Proposed Sale	21.67	180,096	3,903,251		Mar 06 04:17 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 03 '25	Option Exercise	2.24	62,525	140,056	241,819	Mar 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 03 '25	Sale	22.98	62,975	1,446,933	188,564	Mar 05 05:00 PM
Del Carmen Jeffrey	Chief Commercial Officer	Mar 03 '25	Sale	22.89	30,423	696,382	0	Mar 05 05:00 PM
INGENITO GARY	Officer	Mar 05 '25	Proposed Sale	22.09	44,904	991,911		Mar 05 04:09 PM
Elsbernd Brian	Officer	Mar 03 '25	Proposed Sale	22.97	62,525	1,436,446		Mar 03 04:21 PM
Del Carmen Jeffrey	Officer	Mar 03 '25	Proposed Sale	22.89	30,423	696,382		Mar 03 10:21 AM
DENKHAUS DONALD A	Director	Jan 08 '25	Option Exercise	2.24	50,000	112,000	491,079	Jan 10 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 13 '24	Option Exercise	4.01	235,000	942,350	921,996	Dec 17 05:24 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 10 '24	Option Exercise	4.01	50,000	200,500	736,996	Dec 11 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 10 '24	Sale	21.93	50,000	1,096,350	686,996	Dec 11 05:00 PM
O'Keeffe Charles B	Director	Dec 10 '24	Option Exercise	4.01	40,000	160,400	727,137	Dec 11 05:00 PM
Miller Steve	Officer	Dec 10 '24	Proposed Sale	21.93	50,000	1,096,333		Dec 10 12:55 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 27 '24	Option Exercise	4.01	12,000	48,120	63,391	Nov 29 08:09 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 27 '24	Sale	22.72	12,000	272,654	51,391	Nov 29 08:09 PM
Harper Molly	Director	Nov 27 '24	Option Exercise	5.78	17,500	101,150	17,500	Nov 29 08:09 PM
Harper Molly	Director	Nov 27 '24	Sale	22.00	17,500	385,000	0	Nov 29 08:09 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Nov 26 '24	Option Exercise	4.01	60,000	240,600	175,133	Nov 29 08:08 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Nov 26 '24	Sale	21.63	13,256	286,704	165,377	Nov 29 08:08 PM
INGENITO GARY	Officer	Nov 27 '24	Proposed Sale	22.72	12,000	272,653		Nov 27 02:42 PM
Harper Molly	Director	Nov 27 '24	Proposed Sale	22.00	17,500	385,000		Nov 27 09:42 AM
Elsbernd Brian	Officer	Nov 26 '24	Proposed Sale	21.63	13,256	286,705		Nov 26 12:37 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 20 '24	Option Exercise	4.01	38,000	152,380	89,391	Nov 22 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 20 '24	Sale	21.20	38,000	805,562	51,391	Nov 22 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 19 '24	Option Exercise	3.54	98,345	348,141	4,576,514	Nov 21 05:11 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 20 '24	Option Exercise	3.54	72,500	256,650	4,550,669	Nov 21 05:11 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 19 '24	Sale	21.19	98,345	2,083,734	4,478,169	Nov 21 05:11 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 20 '24	Sale	21.29	72,500	1,543,525	4,478,169	Nov 21 05:11 PM
INGENITO GARY	Officer	Nov 20 '24	Proposed Sale	21.20	38,000	805,543		Nov 20 03:49 PM
MCENANY PATRICK J	Director	Nov 20 '24	Proposed Sale	21.29	72,500	1,543,555		Nov 20 02:57 PM
MCENANY PATRICK J	Director	Nov 19 '24	Proposed Sale	21.19	98,345	2,083,726		Nov 19 04:09 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 13 '24	Option Exercise	3.54	92,500	327,450	4,570,669	Nov 15 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 14 '24	Option Exercise	3.54	44,655	158,079	4,522,824	Nov 15 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 13 '24	Sale	22.98	92,500	2,125,465	4,478,169	Nov 15 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 14 '24	Sale	21.75	44,655	971,336	4,478,169	Nov 15 05:00 PM
MCENANY PATRICK J	Director	Nov 14 '24	Proposed Sale	21.75	44,655	971,327		Nov 14 04:12 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 12 '24	Option Exercise	3.67	262,000	960,380	4,670,169	Nov 13 05:44 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 11 '24	Option Exercise	4.01	230,000	922,300	4,708,169	Nov 13 05:44 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 12 '24	Sale	23.26	262,000	6,094,062	4,478,169	Nov 13 05:44 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 11 '24	Sale	23.55	230,000	5,416,040	4,478,169	Nov 13 05:44 PM
MCENANY PATRICK J	Former Director	Nov 13 '24	Proposed Sale	22.98	92,500	2,125,997		Nov 13 04:04 PM
MCENANY PATRICK J	Director	Nov 12 '24	Proposed Sale	23.16	70,000	1,620,856		Nov 12 04:11 PM
MCENANY PATRICK J	Director	Nov 12 '24	Proposed Sale	23.30	192,000	4,473,224		Nov 12 02:13 PM
MCENANY PATRICK J	Director	Nov 11 '24	Proposed Sale	23.55	230,000	5,416,009		Nov 12 10:52 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CPRX

Catalyst Pharmaceuticals Inc

Upgrade your FINVIZ experience